The approval for Hipra’s Covid-19 vaccine was based on an immunobridging study comparing the efficacy of Bimervax with Pfizer and BioNTech’s mRNA vaccine, Comirnaty. Image Credit: Ansty / Shutterstock.

Accord Healthcare has announced an exclusive commercialisation agreement for a Covid-19 vaccine manufactured by Spanish biotech Hipra in the UK.

Bimervax is a bivalent recombinant protein vaccine based on alpha and beta variants of SARS-CoV-2.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It was authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a booster vaccine that provides active immunisation against Covid-19 in people aged 16 years and older on 31 July 2023. It is also authorised for use in the European Union (EU).

However, this marketing agreement comes after a recent EMA decision to seek Covid-19 vaccines that specifically target the SARS-CoV-2 XBB 1.5 Omicron subvariant.

Hipra has an existing contract, announced in 2022, with the Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC) for Bimervax. The agreement allows for the procurement of 250 million doses of the vaccine.

See Also:

The approval for Hipra’s Covid-19 vaccine was based on an immunobridging study comparing the efficacy of Bimervax with Pfizer and BioNTech’s mRNA vaccine, Comirnaty.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the press release, Hipra managing director Carles Fàbrega said: “The Hipra Covid-19 vaccine is the first human health vaccine to be designed, developed and fully manufactured in Spain.

“Having the structures and capabilities ranging from the most basic research and development to the production of vaccines in the country is a key factor in being able to support a rapid response in the event of future health emergencies and reinforces the strategic autonomy of Europe in the field of health.”

Last month, the European Medicines Agency (EMA) recently granted full approval for Novavax’s Matrix-M adjuvant protein-based Covid-19 vaccine (Nuvaxovid). The vaccine is approved as a primary vaccine for people 12 years of age and older and as a booster dose for adults aged 18 and older.

Moderna has filed for EMA approval for a modified version of its mRNA vaccine based on a SARS-CoV-2 variant.